Cupid Limited
CUPID · NSE · Consumer Defensive
With a 20% margin of safety, our buy-below price is ₹65.96. Low-confidence estimate — limited data.
Piotroski F-score 4/9 — quality of earnings & balance sheet.
Investability checklist
- ✓ROE above 15%27.3%
- ✓Low debt (D/E < 0.5)0.13x
- ✓Positive free cash flow
- ✓Revenue growth > 10%112%
- ✓Earnings growing214%
- ✓Net margin ≥ 10%28.9%
- ✓Current ratio > 1.54.67
- ✕Below our fair value
- ✕Margin of safety ≥ 20%
- ✓Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 131.1
- ✕Piotroski ≥ 74/9
1-year price
EOD · 2026-06-16Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Annual financials
Shareholding
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
SWOT snapshot
Strengths
- •Strong return on equity (27.3%).
- •Lightly leveraged balance sheet.
- •Healthy profit margin (28.9%).
- •Trading near its 52-week high.
- •Financially solid — Altman Z 131.1.
Opportunities
- •Earnings growing (214% YoY).
- •Revenue growing (112% YoY).
Threats
- •Rich valuation versus sector peers.
- •Trades ~50% above our estimated fair value.
About Cupid Limited
Cupid Limited designs, manufactures, markets, and exports male and female condoms in India. The company offers water based lubricant jellies; in vitro diagnostic kits, including rapid diagnostic, viral transport medium, typhoid antibody, syphilis antibody, HIV 1 and 2 kit antibody, dengue IgG/IgM, malaria Pf-Pv and Pf-PAN antigen, hepatitis B (HbsAg) antigen, hepatitis C (HCV) antibody, pregnancy detection testing kit, LH ovulation testing kit, and dengue NS1 testing kit; and
More in Consumer Defensive
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.